glp 1 6 in 1 oral liquid reviews glp-1 RACGP glp-1 6 in 1 oral

Retatrutides phase 3 topline data reported adverse events broadly consistent with incretin-based therapies, with nausea, diarrhea, constipation, and vomiting among the most common

This is not a full list of potential side effects

The approval stems from the Phase IIIb SOUL trial involving over 9,600 patients, which showed MACE occurred in 12% of Rybelsus-treated patients versus 13.8% on placeboa statistically significant 14% treatment effect

The distinction matters enormously for your long-term outcome

Dunbar Matos says shes seen no evidence of these in her patients, but more studies would need to be done to evaluate these concerns